#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating patients with anxiety, PTSD, and depression need this evidence to counter patient requests for cannabis as a mental health treatment, since the review shows cannabis lacks efficacy for these common conditions. Patients may benefit from knowing that despite cannabis’s popularity as a self-medication strategy, evidence-based treatments like psychotherapy and antidepressants remain the standard of care for mental health disorders. This finding helps clinicians direct limited healthcare resources toward interventions with demonstrated benefit rather than unproven alternatives.
A comprehensive systematic review has found insufficient evidence supporting cannabis as an effective treatment for anxiety disorders, post-traumatic stress disorder, and other common mental health conditions, contradicting widespread patient beliefs and some clinical practices. This analysis pooled data across multiple studies and found that existing research does not demonstrate clinically meaningful benefits for these indications, and some evidence suggests potential for harm including worsening anxiety or mood symptoms. The findings are particularly relevant given the growing number of patients self-medicating with cannabis for mental health rather than pursuing evidence-based treatments such as psychotherapy or FDA-approved medications. Clinicians should be aware that recommending or endorsing cannabis for anxiety, depression, or PTSD lacks robust scientific support and may delay patients from accessing proven interventions. When patients inquire about cannabis for mental health symptoms, physicians should discuss the lack of efficacy evidence while reinforcing the established benefits of conventional psychiatric treatments.
“After two decades of seeing patients reach for cannabis hoping it will manage their anxiety or depression, I can tell you the evidence now matches what careful observation has always suggested: we’re not seeing sustained mental health improvements, and for many people we’re seeing the opposite. The cannabinoid ratios and dosing regimens we use in other conditions simply don’t translate to psychiatric care, and patients deserve to know that before they self-medicate into a cycle of dependence.”
💭 A recent systematic review challenging cannabis efficacy for anxiety, PTSD, and other mental health conditions warrants careful clinical attention, though the evidence landscape remains genuinely complex. Most randomized controlled trials in this space have been small, short-term, and often focused on specific cannabinoid formulations rather than the heterogeneous products patients actually use, making it difficult to draw definitive conclusions about all cannabis preparations or all patient populations. Additionally, the review’s findings may reflect publication bias, differences in outcome measurement, and the challenge of conducting rigorous trials in a federally restricted substance where clinical equipoise remains uncertain. Clinicians should interpret these findings not as conclusive evidence that cannabis never helps any patient, but rather as a signal that existing evidence does not currently support recommending cannabis as a first-line or empirically validated treatment for anxiety or PTSD. Given the lack of robust efficacy data and the potential for cannabis use to worsen anxiety or
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: